Why vitamin D for cancer patients?

Por Gandini, S, Francesco, FP, Johanson, H, Bonanni, B, Testori, A
Publicado em 2009

Report from the Melanoma Independent Board First Melanoma MIB Conference, 21–22 October 2013

Por Testori, A, Ascierto, P, Chiarion Sileni, V, De Lorenzo, F, Pelicci, PG, Rossi, CR
Publicado em 2014

Surgery and radiotherapy in the treatment of cutaneous melanoma

Por Testori, A., Rutkowski, P., Marsden, J., Bastholt, L., Chiarion-Sileni, V., Hauschild, A., Eggermont, A. M. M.
Publicado em 2009

Surgical management of melanoma: an EORTC Melanoma Group survey

Por Testori, A, Soteldo, J, Powell, B, Sales, F, Borgognoni, L, Rutkowski, P, Lejeune, F, van Leeuwen, PAM, Eggermont, A
Publicado em 2013

Utility of adjuvant systemic therapy in melanoma

Por Eggermont, A. M. M., Testori, A., Marsden, J., Hersey, P., Quirt, I., Petrella, T., Gogas, H., MacKie, R. M., Hauschild, A.
Publicado em 2009

Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia

Por Burt, RK, Testori, A, Oyama, Y, Rodriguez, HE, Yaung, K, Villa, M, Bucha, JM, Milanetti, F, Sheehan, J, Rajamannan, N, Pearce, WH
Publicado em 2009

A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

Por Rocca, A, Minucci, S, Tosti, G, Croci, D, Contegno, F, Ballarini, M, Nolè, F, Munzone, E, Salmaggi, A, Goldhirsch, A, Pelicci, P G, Testori, A
Publicado em 2009

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial

Por Leyvraz, S., Piperno-Neumann, S., Suciu, S., Baurain, J. F., Zdzienicki, M., Testori, A., Marshall, E., Scheulen, M., Jouary, T., Negrier, S., Vermorken, J. B., Kaempgen, E., Durando, X., Schadendorf, D., Gurunath, R. Karra, Keilholz, U.
Publicado no Ann Oncol (2014)

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

Por Chiarion-Sileni, V, Pigozzo, J, Ascierto, P A, Simeone, E, Maio, M, Calabrò, L, Marchetti, P, De Galitiis, F, Testori, A, Ferrucci, P F, Queirolo, P, Spagnolo, F, Quaglino, P, Carnevale Schianca, F, Mandalà, M, Di Guardo, L, Del Vecchio, M
Publicado em 2014

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

Por Saiag, P., Gutzmer, R., Ascierto, P. A., Maio, M., Grob, J.-J., Murawa, P., Dreno, B., Ross, M., Weber, J., Hauschild, A., Rutkowski, P., Testori, A., Levchenko, E., Enk, A., Misery, L., Vanden Abeele, C., Vojtek, I., Peeters, O., Brichard, V. G., Therasse, P.
Publicado no Ann Oncol (2016)

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

Por Gutzmer, R, Rivoltini, L, Levchenko, E, Testori, A, Utikal, J, Ascierto, P A, Demidov, L, Grob, J J, Ridolfi, R, Schadendorf, D, Queirolo, P, Santoro, A, Loquai, C, Dreno, B, Hauschild, A, Schultz, E, Lesimple, T P, Vanhoutte, N, Salaun, B, Gillet, M, Jarnjak, S, De Sousa Alves, P M, Louahed, J, Brichard, V G, Lehmann, F F
Publicado no ESMO Open (2016)